亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

5-Year Outcomes After Left Atrial Appendage Closure

医学 心房颤动 华法林 随机对照试验 心脏病学 临床终点 内科学 外科 冲程(发动机) 机械工程 工程类
作者
Vivek Y. Reddy,Shephal K. Doshi,Saibal Kar,Douglas Gibson,Matthew J. Price,Kurt Huber,Rodney Horton,Maurice Buchbinder,Petr Neužil,Nicole Gordon,David R. Holmes
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:70 (24): 2964-2975 被引量:803
标识
DOI:10.1016/j.jacc.2017.10.021
摘要

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. Paul, Minnesota) was equivalent to warfarin for preventing stroke in atrial fibrillation, but had a high rate of complications. In a second randomized trial, PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), the complication rate was low. The warfarin cohort experienced an unexpectedly low ischemic stroke rate, rendering the efficacy endpoints inconclusive. However, these outcomes were based on relatively few patients followed for a relatively short time. The final results of the PREVAIL trial, both alone and as part of a patient-level meta-analysis with the PROTECT AF trial, are reported with patients in both trials followed for 5 years. PREVAIL and PROTECT AF are prospective randomized clinical trials with patients randomized 2:1 to LAAC or warfarin; together, they enrolled 1,114 patients for 4,343 patient-years. Analyses are by intention-to-treat, and rates are events per 100 patient-years. For the PREVAIL trial, the first composite coprimary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority (posterior probability for noninferiority = 88.4%), whereas the second coprimary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority (posterior probability for noninferiority = 97.5%); the warfarin arm maintained an unusually low ischemic stroke rate (0.73%). In the meta-analysis, the composite endpoint was similar between groups (hazard ratio [HR]: 0.820; p = 0.27), as were all-stroke/SE (HR: 0.961; p = 0.87). The ischemic stroke/SE rate was numerically higher with LAAC, but this difference did not reach statistical significance (HR: 1.71; p = 0.080). However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplained death, all-cause death, and post-procedure bleeding favored LAAC (HR: 0.20; p = 0.0022; HR: 0.45; p = 0.03; HR: 0.59; p = 0.027; HR: 0.73; p = 0.035; HR: 0.48; p = 0.0003, respectively). These 5-year outcomes of the PREVAIL trial, combined with the 5-year outcomes of the PROTECT AF trial, demonstrate that LAAC with Watchman provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mortality. (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation; NCT00129545; and Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy; NCT01182441)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
juan完成签到 ,获得积分10
1分钟前
学术小垃圾完成签到,获得积分10
1分钟前
叁月二完成签到 ,获得积分10
1分钟前
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
大模型应助科研通管家采纳,获得10
1分钟前
xingsixs完成签到 ,获得积分10
2分钟前
AprilLeung完成签到 ,获得积分10
3分钟前
3分钟前
深情安青应助科研通管家采纳,获得10
3分钟前
迷茫的一代完成签到,获得积分10
4分钟前
魔笛的云宝完成签到 ,获得积分10
4分钟前
www完成签到,获得积分10
5分钟前
5分钟前
NexusExplorer应助科研通管家采纳,获得10
5分钟前
Akitten发布了新的文献求助10
6分钟前
啥时候吃火锅完成签到 ,获得积分0
7分钟前
上官若男应助科研通管家采纳,获得30
7分钟前
斯文败类应助科研通管家采纳,获得10
7分钟前
李爱国应助科研通管家采纳,获得10
7分钟前
科研通AI2S应助科研通管家采纳,获得10
7分钟前
赘婿应助科研通管家采纳,获得10
7分钟前
田様应助精明晓刚采纳,获得10
8分钟前
8分钟前
精明晓刚发布了新的文献求助10
8分钟前
科研通AI2S应助科研通管家采纳,获得10
9分钟前
coolplex完成签到 ,获得积分10
10分钟前
wwe完成签到,获得积分10
10分钟前
貔貅完成签到 ,获得积分10
11分钟前
yindi1991完成签到 ,获得积分10
13分钟前
hgl完成签到,获得积分10
13分钟前
13分钟前
科研通AI2S应助科研通管家采纳,获得10
13分钟前
13分钟前
华仔应助精明晓刚采纳,获得10
14分钟前
14分钟前
14分钟前
精明晓刚发布了新的文献求助10
14分钟前
糖伯虎完成签到 ,获得积分10
15分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990423
求助须知:如何正确求助?哪些是违规求助? 3532158
关于积分的说明 11256513
捐赠科研通 3271046
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234